tirzepatide - medicine shortage information

Back to ALL shortages and discontinuations Back to CRITICAL shortages and discontinuations

If you are having difficulty obtaining a medicine that has been prescribed to you, talk to your doctor or pharmacist to discuss suitable options to continue your care.

More information about medicine shortages and how to access alternative medicines is available at the Medicine Shortages hub

Sort by: Updated date | Shortage status | Trade name

Product details	Supply Impact Dates	Further Details
MOUNJARO tirzepatide 10 mg/0.5 mL solution for injection vial AUST R: 407053 Active ingredients: tirzepatide Dosage form: Injection, solution Sponsor: Eli Lilly Australia Pty Ltd Phone: 1800 454 559	From 22 Nov 2023 to 31 Aug 2025	Shortage status: Current Availability: Unavailable Reason: Commercial Changes / Commercial viability Management action: An unregistered product has been approved for supply under Section 19A. See the website: https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections
MOUNJARO tirzepatide 12.5 mg/0.5 mL solution for injection vial AUST R: 407052 Active ingredients: tirzepatide Dosage form: Injection, solution Sponsor: Eli Lilly Australia Pty Ltd Phone: 1800 454 559	From 22 Nov 2023 to 31 Aug 2025	Shortage status: Current Availability: Unavailable Reason: Commercial Changes / Commercial viability Management action: An unregistered product has been approved for supply under Section 19A. See the website: https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections
MOUNJARO tirzepatide 15 mg/0.5 mL solution for injection vial AUST R: 407054 Active ingredients: tirzepatide Dosage form: Injection, solution Sponsor: Eli Lilly Australia Pty Ltd Phone: 1800 454 559	From 22 Nov 2023 to 31 Aug 2025	Shortage status: Current Availability: Unavailable Reason: Commercial Changes / Commercial viability Management action: An unregistered product has been approved for supply under Section 19A. See the website: https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections
MOUNJARO tirzepatide 2.5 mg/0.5 mL solution for injection vial AUST R: 407055 Active ingredients: tirzepatide Dosage form: Injection, solution Sponsor: Eli Lilly Australia Pty Ltd Phone: 1800 454 559	From 22 Nov 2023 to 31 Aug 2025	Shortage status: Current Availability: Unavailable Reason: Commercial Changes / Commercial viability Management action: An unregistered product has been approved for supply under Section 19A. See the website: https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections
MOUNJARO tirzepatide 5 mg/0.5 mL solution for injection vial AUST R: 407050 Active ingredients: tirzepatide Dosage form: Injection, solution Sponsor: Eli Lilly Australia Pty Ltd Phone: 1800 454 559	From 22 Nov 2023 to 31 Aug 2025	Shortage status: Current Availability: Limited Availability Reason: Commercial Changes / Commercial viability Management action: An unregistered product has been approved for supply under Section 19A. See the website: https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections
MOUNJARO tirzepatide 7.5 mg/0.5 mL solution for injection vial AUST R: 407051 Active ingredients: tirzepatide Dosage form: Injection, solution Sponsor: Eli Lilly Australia Pty Ltd Phone: 1800 454 559	From 22 Nov 2023 to 31 Aug 2025	Shortage status: Current Availability: Unavailable Reason: Commercial Changes / Commercial viability Management action: An unregistered product has been approved for supply under Section 19A. See the website: https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections